[CLSTR]
< Back to all clusters
[BUSINESS] · United Kingdom, United States, Japan, China · 30 sources

started · updated

AstraZeneca beats Q2 forecasts as oncology sales rise, but Ultomiris misses late‑stage trial goal

AstraZeneca Q2 earnings oncology sales Ultomiris trial failure $80bn revenue target

AstraZeneca reported second‑quarter 2026 earnings that topped analyst expectations. Net profit rose by more than 2 % to about $2.51 billion, while total revenue increased 5 % to roughly $15.38 billion on a constant‑currency basis. Oncology sales grew between 15 % and 16 % year‑on‑year, driven by flagship drugs such as Tagrisso, Imfinzi, Calquence, Lynparza and Enhertu.

At the same time, the company disclosed a setback in its rare‑disease pipeline: the late‑stage trial of Ultomiris (ravulizumab) did not achieve statistical significance for event‑free survival at 26 weeks in patients with haematopoietic‑stem‑cell‑transplant‑associated thrombotic microangiopathy. A separate paediatric study showed overall survival of 87.2 % at 26 weeks and 73.4 % at 52 weeks, prompting the company to advance regulatory filings for the pediatric indication.

AstraZeneca also announced that its experimental gastric‑cancer antibody‑drug conjugate sonesitatug vedotin met its primary endpoint, delivering a statistically significant overall‑survival benefit. CEO Pascal Soriot reiterated the target of $80 billion in annual revenue by 2030. Earlier in June, data from a weight‑loss study showed the experimental pill elecoglipron produced an average 10.5 % body‑weight loss after 26 weeks and 11.8 % after 36 weeks.

Entities

AstraZeneca · AstraZeneca plc · Enlarged cancer portfolio · Pascal Soriot · Sonesitatug vedotin · Tagrisso · Ultomiris · Ultomiris (ravulizumab) · elecoglipron

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

Grifols Q2 Earnings Call Highlights [www.marketbeat.com]
RESULTADOS EMPRESARIALES | Grifols eleva un 28% sus beneficios en el primer semestre, pese a reducir ligeramente sus ingresos [www.diariodemallorca.es]
RESULTADOS EMPRESARIALES | Grifols eleva un 28% sus beneficios en el primer semestre, pese a reducir ligeramente sus ingresos [www.eldia.es]
AstraZeneca: Krebsmittel treiben Gewinn - Aktie legt zu [www.finanznachrichten.de]
AstraZeneca crece 5% en ventas semestrales [www.pharmabiz.net]
AstraZeneca’s rare disease drug misses main goal in late-stage trial [wdez.com]
AstraZeneca’s rare disease drug misses main goal in late-stage trial [mix929.com]
AstraZeneca’s rare disease drug misses main goal in late-stage trial [jack1065.com]
AstraZeneca: Quartalszahlen, Core-EPS und Onkologie-Studien stärken die Wachstumserwartung [www.it-boltwise.de]
Celyad Oncology: Tolefi SA passe sous le seuil de 10% du capital [www.abcbourse.com]
RESULTADOS EMPRESARIALES | Grifols eleva un 28% sus beneficios en el primer semestre, pese a reducir ligeramente sus ingresos [www.farodevigo.es]
RESULTADOS EMPRESARIALES | Grifols eleva un 28% sus beneficios en el primer semestre, pese a reducir ligeramente sus ingresos [www.lne.es]
Grifols eleva un 28% su beneficio hasta junio: "Empieza a respirar", según Pinto [www.capitalradio.es]
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve [www.hospitalmanagement.net]
Les bénéfices d'AstraZeneca dépassent les prévisions grâce à une forte hausse des ventes dans le domaine de l'oncologie [fr.businessam.be]
PRISA dispara sus ganancias en 2026: crecen un 70% y revela el fuerte avance de EL PAÍS y Santillana [www.futuro.cl]
PRISA eleva un 70% su EBITDA y mejora sus ingresos durante el primer semestre de 2026 [www.concierto.cl]
RESULTADOS EMPRESARIALES | Grifols eleva un 28% sus beneficios en el primer semestre, pese a reducir ligeramente sus ingresos [www.elperiodicoextremadura.com]
AstraZeneca affiche un bénéfice net en hausse grâce à l’oncologie – Entrevue [entrevue.fr]
AstraZeneca steigert Quartalsgewinn um zwei Prozent dank starker Krebsmedikamente [de.euronews.com]
Az AstraZeneca negyedéves nettó nyeresége 2%-kal nő az erős rákgyógyszer-eladásoknak köszönhetően [hu.euronews.com]
AstraZeneca se dispara en bolsa tras superar las expectativas [es.euronews.com]
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View [www.finanzen.at]
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View [www.finanzen.ch]
Krebsmittel treiben Wachstum von Astrazeneca an [www.moneycab.com]
AstraZeneca’s rare disease drug misses main goal in late-stage trial [wsau.com]
Grifols gana un 29% más hasta junio por el tirón de Biopharma [www.expansion.com]
BERENBERG stuft ASTRAZENECA auf 'Buy' [www.finanznachrichten.de]
AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN) | Seeking Alpha [seekingalpha.com]
AstraZeneca quarterly net profit rises 2% on strong cancer drug sales [www.euronews.com]